血清半乳糖凝集素-9作为无创生物标志物检测子宫内膜异位症及盆腔痛或不孕相关妇科疾病
前瞻性病例对照研究纳入135名育龄女性,包括77例子宫内膜异位症患者、28例妇科对照和30例健康女性,评估血清可溶性半乳糖凝集素-9(Gal-9)的诊断价值。结果发现,在 cut-off 值132 pg/mL下,Gal-9 ELISA诊断子宫内膜异位症的曲线下面积为0.973,灵敏度94%,特异度93.75%,且轻度-轻度(I-II)和中度-重度(III-IV)期子宫内膜异位症患者Gal-9水平均显著高于健康对照。作者认为Gal-9可能是有前景的无创生物标志物。
要点
- 在 cut-off 值132 pg/mL下,Gal-9诊断子宫内膜异位症的AUC为0.973,灵敏度94%,特异度93.75%。
- 轻度-轻度(I-II)和中度-重度(III-IV)期子宫内膜异位症患者血清Gal-9水平均显著高于健康对照。
- 多种盆腔痛或不孕相关良性妇科疾病也伴有血清Gal-9水平升高。
核心结论
- 作者认为,Gal-9可能是子宫内膜异位症的有前景的无创生物标志物,并可作为多种不孕或盆腔痛相关妇科疾病的预测指标。
研究设计与样本
- 前瞻性病例对照研究,纳入135名育龄女性,包括77例子宫内膜异位症患者、28例妇科对照和30例健康女性。
主要发现
- 在 cut-off 值132 pg/mL下,Gal-9 ELISA诊断子宫内膜异位症的曲线下面积为0.973,灵敏度为94%,特异度为93.75%。
- 轻度-轻度(I-II)和中度-重度(III-IV)期子宫内膜异位症患者的血清Gal-9水平均显著高于健康对照。
- 多种盆腔痛或不孕相关的良性妇科疾病也与血清Gal-9水平升高相关。
关键数值与推荐
- Gal-9 ELISA诊断子宫内膜异位症的 cut-off 值为132 pg/mL,曲线下面积为0.973,灵敏度94%,特异度93.75%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the usefulness of soluble galectin-9 (Gal-9) in the noninvasive laboratory diagnosis of endometriosis and various gynecologic disorders. DESIGN: Prospective case-control study. SETTING: University medical centers. PATIENT(S): A total of 135 women of reproductive age were involved in the study, 77 endometriosis patients, 28 gynecologic controls, and 30 healthy women. INTERVENTION(S): Diagnostic laparoscopy and collection of tissue biopsies, peritoneal cells, and native peripheral blood from different case groups of gynecology patients and healthy women. MAIN OUTCOME MEASURE(S): The expression of mRNA and serum concentration of Gal-9. RESULT(S): Semiquantitative reverse transcription-polymerase chain reaction analysis and serum soluble Gal-9 ELISA were performed on three different cohorts of patients: those with endometriosis, those with benign gynecologic disorders, and healthy controls. Differences in the Gal-9 concentrations between the investigated groups and the stability of Gal-9 in the serum and diagnostic characteristics of Gal-9 ELISA were determined by statistical evaluation and receiver operating characteristic (ROC) curve analysis. Significantly elevated Gal-9 levels were found in both minimal-mild (I-II) and moderate-severe (III-IV) stages of endometriosis in comparison with healthy controls. At a cutoff of 132 pg/mL, ROC analysis revealed an excellent diagnostic value of Gal-9 ELISA in endometriosis (area under the curve = 0.973) with a sensitivity of 94% and specificity of 93.75%, indicating better diagnostic potential than that of other endometriosis biomarkers. Furthermore, various pelvic pain or infertility-associated benign gynecologic conditions were also associated with increased serum Gal-9 levels. CONCLUSION(S): Our results suggest that Gal-9 could be a promising noninvasive biomarker of endometriosis and a predictor of various infertility or pelvic pain-related gynecologic disorders.
引用
- Brubel R, Bokor A, Pohl A, et al. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertil Steril. 2017. PMID: 29202955. doi:10.1016/j.fertnstert.2017.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。